• KOL
    • Chronic Hepatitis
    • Anna Shuk‐fong Lok
    • Anna Shuk‐Fong Lok: Influence Statistics

      Anna Shuk‐Fong Lok

      Anna Shuk‐Fong Lok

      Show email address

      Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Ann Arbor, MI, USA | Division of Gastroenterology and Hepatology, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Anna Shuk‐Fong Lok:Expert Impact

      Concepts for whichAnna Shuk‐Fong Lokhas direct influence:Chronic hepatitis,Hepatocellular carcinoma,United states,Hepatitis virus,Antiviral therapy,Liver transplantation,Liver disease,Viral hepatitis.

      Anna Shuk‐Fong Lok:KOL impact

      Concepts related to the work of other authors for whichfor which Anna Shuk‐Fong Lok has influence:Chronic hepatitis,Hepatocellular carcinoma,Liver fibrosis,Hbv infection,Antiviral therapy,Hcc patients.

      KOL Resume for Anna Shuk‐Fong Lok

      Year
      2022

      Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Ann Arbor, MI, USA

      2021

      Department of Internal Medicine, University of Michigan, Ann Arbor, MI

      Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.

      2020

      Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor

      2019

      Division of Gastroenterology and Hepatology, University of Michigan, 1500 E Medical Center Drive, 3912 Taubman Center, SPC 5362, 48109, Ann Arbor, MI, USA

      University of Michigan, Ann Arbor, MI

      2018

      Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America

      Jessica P. Hwang, Scott B. Cantor, Andrea Barbo, Heather Y. Lin, Jessica T. Foreman, Harrys A. Torres, Bruno P. Granwehr, Ethan Miller, Cathy Eng, George R. Simon, Sairah Ahmed, Alessandra Ferrajoli, Jorge Romaguera, and Maria E. Suarez-Almazor, The University of Texas MD Anderson Cancer Center; John M. Vierling, Baylor College of Medicine, Houston, TX; Anna S. Lok, University of Michigan, Ann Arbor, MI; and Michael J. Fisch, Aim Specialty Health, Chicago, IL.

      Department of Internal Medicine and Gastroenterology, University of Michigan, Ann Arbor, Michigan.

      Institute for Healthcare Policy and Innovation, Ann Arbor, MI, USA

      VA Center for Clinical Management Research, Ann Arbor, MI, United States

      2017

      Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI 48109, USA.

      From University of Michigan, Ann Arbor, Michigan; Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Phoenix, Arizona; Duke University School of Medicine, Durham, North Carolina; and Washington University School of Medicine, St. Louis, Missouri.

      University of Michigan Department of Internal Medicine Ann Arbor, Michigan U.S.A

      2016

      University of Michigan Health System, 1500 E Medical Center Drive, 3912 Taubman Center, SPC 5362, 48109, Ann Arbor, MI, USA

      Univ. of Michigan (United States)

      2015

      Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor

      2014

      University of Michigan Health System Division of Gastroenterology Department of Internal Medicine Ann Arbor MI USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Anna Shuk‐Fong Lok is among the top experts in the world.
      Concept World rank
      participants sanger sequencing #1
      hbv screening chemotherapy #1
      m4 association #1
      hbv infection setting #1
      baseline gds scores #1
      outcome antiviral #1
      comorbidities hit6 #1
      patients advanced hepatitis #1
      topic coinfection dna #1
      hbv vls #1
      hepatocyte ros #1
      ccc hbv dna #1
      late stage absence #1
      dri opo #1
      healed ulcer density #1
      avt incidence #1
      illness chronic humans #1
      earlier hbeag seroconversion #1
      22 gfr #1
      pi∗ms genotype #1
      35 years treatment #1
      maintenance therapy reduction #1
      hbv v3 #1
      graft failure a2all #1
      new hepatitis virus #1
      midtreatment response #1
      hcv msas #1
      liver centre #1
      odds recommendations #1
      cirrhosis diseases #1
      hbv cure development #1
      discovery regulatory approval #1
      ast ldlt #1
      pretransplant treatment hcv #1
      cirrhosis pi∗mz genotype #1
      postlt gfr #1
      cost effectiveness interferonα2b #1
      hcc clinical outcomes #1
      nucleoside resistance development #1
      controls hbv dna #1
      lower observed #1
      virologic null #1
      ymdd motif resistance #1
      tma consistently positive #1
      hbv patients olt #1
      hbvdna prerequisite #1
      p21 effects #1
      lean americans #1
      immune tolerant phase #1
      hbv recurrence caucasians #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Anna Shuk‐Fong Lok

      KOL-Index: 18502

      Variants in the precore (G(1896)A) and core promoter (A(1762)T, G(1764)A) regions of hepatitis B virus (HBV) may be related to serum HBV DNA levels and severity of liver disease. The aims of this nationwide study were to determine the prevalence of HBV precore/core promoter variants in the United States and the association between these variants and patient demographics, HBV genotypes, serum HBV DNA level, and severity of liver disease. A total of 694 consecutive chronic HBV-infected ...

      Known for United States | Core Promoter | Hbv Genotypes | Antigens Hepatitis | Liver Disease
      KOL-Index: 18323

      BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.

      METHODS: In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to ...

      Known for Patients Hcv Genotype | Sustained Virologic Response | Daclatasvir Sofosbuvir | Chronic Hcv | Ribavirin 12 Weeks
      KOL-Index: 18149

      BACKGROUND & AIMS: Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of HBsAg seroclearance vary. We performed a systematic review and meta-analysis to provide more precise estimates of HBsAg seroclearance rates among subgroups and populations.

      METHODS: We searched PubMed, Embase, and the Cochrane library for cohort studies that reported HBsAg seroclearance in adults with ...

      Known for Hbsag Seroclearance | Hbv Infection | Hepatitis Chronic | Patients Hbeag | Cochrane Library
      KOL-Index: 17647

      BACKGROUND & AIMS: The combination of ledipasvir and sofosbuvir has been approved for treatment of genotype 1 hepatitis C virus (HCV) infection, including an 8-week regimen for treatment-naïve patients without cirrhosis and a baseline level of HCV RNA <6 million IU/mL. We analyzed data from a multicenter, prospective, observational study to determine real-world sustained virologic responses 12 weeks after treatment (SVR12) with regimens containing ledipasvir and sofosbuvir and identify ...

      Known for 8 Weeks | Treatment Svr12 | Ledipasvir Sofosbuvir | Sustained Virologic | Virus Infection
      KOL-Index: 16819

      Previous studies reported that hepatitis B virus (HBV) deoxyribonucleic acid (DNA) can be detected in livers of patients who received transplants for hepatitis B despite the absence of serological markers of HBV recurrence. Quantification of HBV DNA was not performed and presence of covalently closed circular (ccc) DNA was not analyzed in most studies. We aimed to quantify total and ccc HBV DNA in explant liver and post-orthotopic liver transplantation (OLT) biopsies and to correlate the ...

      Known for Hbv Dna | Liver Transplantation | Patients Olt | Antiviral Therapy | Hepatitis Virus
      KOL-Index: 16552

      BACKGROUND & AIMS: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We evaluated continued entecavir and lamivudine treatment through 96 weeks.

      METHODS: 709 HBeAg-positive CHB patients were randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355) once daily. At week 52, protocol-defined virologic responders could continue blinded treatment for up to 96 ...

      Known for 96 Weeks | Entecavir Therapy | Hbeag Seroconversion | Positive Chronic | Lamivudinetreated Patients
      KOL-Index: 16476

      BACKGROUND: Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV).

      METHODS: In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a ...

      Known for Entecavir Lamivudine | Chronic Hepatitis | Viral Resistance | Histologic Improvement | P0001 Normalization
      KOL-Index: 16403

      BACKGROUND: In patients with chronic hepatitis C who do not have a response to antiviral treatment, the disease may progress to cirrhosis, liver failure, hepatocellular carcinoma, and death. Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain.

      METHODS: We conducted a randomized, controlled trial of peginterferon alfa-2a at a dosage of 90 microg per week for 3.5 years, as compared with no treatment, in 1050 patients with chronic ...

      Known for Chronic Hepatitis | Patients Peginterferon | Prolonged Therapy | 35 Years | Cirrhosis Response
      KOL-Index: 15799

      BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.

      METHODS: In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end ...

      Known for Patients Entecavir | Chronic Hepatitis | Histologic Improvement | 48 Weeks | Nucleoside Analogue
      KOL-Index: 15544

      Mutations in the core promoter and precore regions are frequently found in hepatitis B e antigen (HBeAg)-negative patients, but precore stop codon mutation is restricted to hepatitis B virus (HBV) genotypes that have T at nucleotide 1858. The aims of this study were to determine the role of core promoter and/or precore mutations in HBeAg seroconversion and their impact on the subsequent course of liver disease, and to determine if core promoter mutations are more frequently selected in ...

      Known for Core Promoter | Hbeag Seroconversion | Virus Genotypes | Patients Hbv | Codon Mutation
      KOL-Index: 15475

      BACKGROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB). We compared the efficacy and safety of ETV monotherapy with those of a combination of ETV and TDF.

      METHODS: We performed a randomized, open-label, multicenter, superiority study of 379 nucleos(t)ide-naïve patients with hepatitis B e antigen (HBeAg)-positive (n = 264) or ...

      Known for Chronic Hepatitis | Disoproxil Fumarate | Etv Tdf | Hbv Dna | Viral Drug Resistance
      KOL-Index: 14992

      Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been implicated in spontaneous and interferon alfa (IFN-alpha)-related hepatitis B e antigen (HBeAg) seroconversion. We performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype and precore/core promoter mutations on IFN-alpha response in patients with HBeAg-positive chronic hepatitis. Clinical data and stored sera from 109 (95%) patients in the ...

      Known for Hbv Genotype | Interferon Therapy | Chronic Hepatitis | Antiviral Response | Viral Drug Resistance
      KOL-Index: 14692

      BACKGROUND & AIMS: Alpha-fetoprotein (AFP) is widely used as a surveillance test for hepatocellular carcinoma (HCC) among patients with cirrhosis. Des-gamma carboxy-prothrombin (DCP) and lectin-bound AFP (AFP-L3%) are potential surveillance tests for HCC. The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels.

      METHODS: We conducted a large phase 2 biomarker ...

      Known for Hepatocellular Carcinoma | Early Hcc | Dcp Afp | United States | 95 Sensitivity
      KOL-Index: 14581

      BACKGROUND & AIMS: Interferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression. We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period.

      METHODS: The ...

      Known for Hcc Patients | Hepatocellular Carcinoma | Advanced Hepatitis | Lower Incidence | Liver Cirrhosis
      KOL-Index: 14204

      The goals of this retrospective study were to determine whether there is a threshold hepatitis B virus (HBV) DNA value associated with spontaneous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value that can be used for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B. HBV DNA levels in sequential serum samples of 165 Chinese patients with different stages of chronic HBV ...

      Known for Hbv Dna | Chronic Hepatitis | Inactive Carriers | Hbeag Loss | Alanine Transaminase

      Key People For Chronic Hepatitis

      Top KOLs in the world
      #1
      Patrick Marcellin
      chronic hepatitis adefovir dipivoxil hcv genotype
      #2
      Michael Peter Manns
      chronic hepatitis liver transplantation hepatocellular carcinoma
      #3
      Anna Shuk‐Fong Lok
      chronic hepatitis hepatocellular carcinoma united states
      #4
      Stefan S Zeuzem
      chronic hepatitis hcv genotype liver fibrosis
      #5
      Jay H Hoofnagle¶¶
      chronic hepatitis liver injury united states
      #6
      Zachary D Goodman
      chronic hepatitis liver fibrosis hepatocellular carcinoma

      Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Ann Arbor, MI, USA | Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electr

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.